Starpharma Holdings Ltd has released a press release.
Starpharma receives $5.7M R&D tax incentive refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Share Purchase Plan offer document
- Starpharma completes oversubscribed A$45M placement
- SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
- Starpharma awarded $1M MRFF funding for COVID-19 spray
- SPL creates slow release soluble DEP remdesivir nanoparticle
Later from Starpharma
- Completion of Placement and SPP raises $48.9M in total
- SPL7013 shows potent antiviral activity in RSV
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
- VIRALEZE COVID-19 nasal spray study to commence in January
- Change in substantial holding
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma